Over 200 million patients (pts) worldwide have fatigue, widespread muscle pain, joint and chest pain due to COIVD-19 infection. Little is known on onset, pathophysiology and clinical history of chronic pain post-COVID, leaving doctors at loss when it comes to specifically identify and diagnose pts and prescribe most effective treatments. To advance knowledge on post-COVID chronic pain, to discuss current clinical gaps, develop potential solutions for these pressing issues we propose a multidisciplinary consortium: -clinicians working with long COVID pts and specific knowledge of chronic post-COVID pain syndrome. -clinical experts in chronic pain syndromes in specific settings: paediatric and chronic postoperative pain, chronic pain neuromodulation; -basic scientists applying genomics for a better understanding of pain pathophysiology and using glycomics to predict long COVID and stratify the risk of pts to develop long COVID associated severe illness; -translational scientists, pharmacology and nanomedicine experts for development of new nanotherapies to tackle chronic pain, inflammation and immune activation; -startups, established biotech companies interested in development of new therapeutic tools for pain, incl.an international CDMO involved in industrialization of pharmaceutical/nutraceutical products, scientific associations (Redirect) for spreading the culture of rational approach to chronic postoperative pain and inflammatory chronic pain.